NAL Pharmaceutical Group Limited Revenue
Pharmaceutical Manufacturing • 
Room 401, No. 93-103 Wing Lok Street, Hong Kong • 1-10 Employees
NAL Pharmaceutical Group Limited revenue & valuation
| Annual revenue | $342,220 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $1,100,000 |
| Total funding | No funding |
Key Contact at NAL Pharmaceutical Group Limited
Noel Lam
Director, Financial Operations
Company overview
| Headquarters | Room 401, No. 93-103 Wing Lok Street,, Shung Wan, Hong Kong 999077, HK |
| Phone number | +85231106888 |
| Website | |
| NAICS | 3254 |
| Keywords | Bio-Cr Oral Controlled-Release Dds Technology, Bio-D3 Transdermal Patch Dds Technology |
| Founded | 2006 |
| Employees | 1-10 |
| Socials |
NAL Pharmaceutical Group Limited Email Formats
NAL Pharmaceutical Group Limited uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@nalpharma.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@nalpharma.com | 66.7% |
{first name}{last name} | johndoe@nalpharma.com | 33.3% |
About NAL Pharmaceutical Group Limited
NAL Pharma is a specialty drug developer that develops novel dosage forms and proprietary drug delivery systems based on the Company’s captive Bio-D3, Bio-FX, Bio-CR, Bio-NN, and Bio-MM Drug Delivery System (“DDS”) technologies. Headquartered in Hong Kong and with operation in the United States, NAL is developing non-infringing, proprietary and improved drug delivery systems that exhibit enhanced patient-compliance, safety, and/or efficacy compared with existing pharmaceutical products, and is also developing specially designed delivery systems to improve conventional dosage forms of new drugs undergoing Phase 2 clinical development that show significant first-pass metabolism side effects, poor solubility, and poor bioavailability. As the US operation of NAL, Galaxy Bio, Inc. ("GBI") has established a captive R&D Laboratory in Princeton, New Jersey, USA for the development of afore-mentioned NAL's innovative and proprietary DDS products. Combining established product formulation and manufacturing development expertise, NAL has developed a number of non-infringing, proprietary and improved therapeutic products that incorporate patent-expiring drugs. NAL is working with major consumer healthcare companies to extend the life cycle of patent expiring drugs for the Rx-to-OTC switch. NAL is also working with major pharmaceutical companies to improve the formulations of their NCE drugs under development, in an effort to develop the most effective delivery systems based on NAL’s proprietary DDS Technologies.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
NAL Pharmaceutical Group Limited has never raised funding before.
NAL Pharmaceutical Group Limited Tech Stack
Discover the technologies and tools that power NAL Pharmaceutical Group Limited's digital infrastructure, from frameworks to analytics platforms.
CDN
Widgets
JavaScript libraries
Miscellaneous
Programming languages
Miscellaneous
JavaScript libraries
Font scripts
United Kingdom
Canada
Portugal
China
United States
Frequently asked questions
4.8
40,000 users
